Author

P. Ruscitti

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Real-world effectiveness and drug retention rate of risankizumab in patients with psoriatic arthritis: data from the multicentre GIRRCS cohort

ABSTRACT Introduction Risankizumab, a selective inhibitor of the IL-23 p19 subunit, has shown efficacy in randomized trials in psoriatic arthritis (PsA); however, real-world data remain limited. We evaluated the effectiveness and treatment persistence of risankizumab in the GIRRCS cohort. Methods This observational stu...

Francesco Caso, E. Celletti, I. Pantano et al. · Expert Opinion on Biological... · 0 citations

Review Open access Sep 2026

Emerging and Investigational JAK Inhibitors for Rheumatoid Arthritis: Efficacy and Safety

Abstract Janus kinase (JAK) inhibition is an established therapeutic strategy in rheumatoid arthritis, but heterogeneous treatment responses, persistent safety concerns, and the need for more precise therapeutic positioning continue to stimulate the development of additional JAK-directed compounds. This structured narr...

Luisa Costa, Francesco Caso, F. Maione et al. · Drug Design, Development and... · 0 citations

Review Open access Aug 2026

Expanding the therapeutic landscape of still’s disease: the emerging role of JAK inhibitors

ABSTRACT Introduction Still’s disease is a systemic inflammatory disorder characterized by a complex cytokine network involving interleukin (IL)-1, IL‑6, IL‑18 and interferon (IFN)-γ. Although IL‑1 and IL‑6 inhibitors represent the cornerstone of current targeted therapy, a subset of patients remains refractory or deve...

P. Ruscitti, F. Ursini, R. Giacomelli et al. · Expert Opinion on Pharmacoth... · 0 citations